A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Inclusion Criteria

• Histologically or cytologically confirmed metastatic or unresectable solid tumor or advanced non-Hodgkin's lymphoma (NHL).
• Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
• Adequate organ and bone marrow function as defined in the protocol.
• For Combination Therapy Expansion:
• Serine/threonine kinase 11/ liver kinase B1 (STK11/LKB1) mutated non-small cell lung cancer (NSCLC) as assessed by historical (local) test.
• Must be refractory to or have progressed on or after a platinum-based doublet regimen and an immune checkpoint inhibitor (CPI). These therapies could have been given in the same line of therapy or different lines of therapy.
• Measurable disease by RECIST version 1.1 as assessed by the Investigator. Key

Exclusion Criteria

• Have a diagnosis of immunodeficiency or are receiving systematic steroid therapy or any other form of immunosuppressive therapy.
• Prior allogeneic transplantation.
• History of cardiac diseases as defined in detail in the protocol.
• Clinically significant infection or any eye infection.
• Active central nervous system (CNS) malignancies (previously treated CNS malignancies are not exclusionary).
• Combination Therapy Expansion:
• Known hypersensitivity or contraindication to pembrolizumab or any of its components.
• Any prior toxicity (Grade 3 or 4) related to immunotherapy leading to treatment discontinuation with the exception of the history of immunotherapy-related endocrinopathy controlled with ongoing medical management (e.g., hypothyroidism, adrenal insufficiency, diabetes).